Prescribing patterns for topical corticosteroids versus advanced targeted topical therapies in chronic inflammatory skin diseases: A 2022-2024 claims analysis.
Burshtein Joshua J, Vender Ronald R, Bunick Christopher C, DiRuggiero Douglas D et al.
Topical corticosteroids (TCSs) have been used since the early 1950s for treatment of inflammatory skin conditions, including atopic dermatitis (AD), psoriasis (PsO), and seborrheic dermatitis (SD). Although effective in treating these conditions, TCSs are associated with notable safety concerns. Advanced targeted topical (ATT) therapies have shown efficacy and safety in dermatologic clinical studies offering an alternative to TCSs. To evaluate real-world prescribing patterns for topical treatment of AD, PsO, and SD since the advent of ATT therapies. Patients with AD, PsO, and/or SD between January 1, 2020 and September 30, 2025 were retrospectively identified from IQVIA's PharMetrics Plus® claims database. Approximately 2.1-2.3 million patients filled AD, PsO, or SD prescriptions yearly from 2022 to 2024. At least 90% of these patients received prescriptions for TCSs, whereas no more than 3% received ATTs. Among patients filling topical therapy prescriptions, at least 96% received TCS prescriptions and no more than 3.2% received ATT prescriptions. Minimal year-to-year decreases in TCS prescriptions (≤ 0.7%) and increases in ATT prescriptions (≤ 0.6%) were seen in patients treated with topical therapies. The advent of ATT therapies has not meaningfully altered the topical treatment landscape for AD, PsO, and SD. Clinicians, payers, and health systems should continue to evaluate prescribing patterns, access barriers, and implementation and real-world evidence to better understand the ongoing role of ATTs and TCSs in clinical practice.